Form 4: Pulse Biosciences Grants Performance-Based Stock Options to Principal Accounting Officer

Pulse Biosciences, Inc. granted 55,000 stock options to Principal Accounting Officer Steven Weber with a $16.03 exercise price, vesting based on time and market capitalization milestones.

Summary

• Steven Weber, Principal Accounting Officer of Pulse Biosciences, Inc. (PLSE), was granted 55,000 stock options.
• The options have an exercise price of $16.03 per share.
• The grant date for these options was July 14, 2025, and they expire on July 14, 2035.
• Half of the shares (27,500) will vest in equal installments on the first, second, third, and fourth anniversaries of the grant date.
• The remaining half of the shares (27,500) will vest upon the achievement of four performance-based vesting criteria, tied to the Issuer's market capitalization reaching between $1.5 billion and $4.0 billion.
• All vesting is contingent upon Mr. Weber's continued service through each milestone.

Sentiment

Score: 7

Explanation: The grant of performance-based options to a key officer is generally positive as it aligns management incentives with shareholder value creation and long-term growth, indicating confidence in future market capitalization targets. It's a routine compensation event, but the performance targets add a positive nuance.

Positives

• Granting of performance-based stock options aligns management incentives with shareholder value creation, specifically targeting market capitalization growth from $1.5 billion to $4.0 billion.
• The time-based vesting component encourages long-term retention of a key officer.

Risks

• Achievement of performance-based vesting criteria is subject to the company's ability to reach significant market capitalization milestones ($1.5 billion to $4.0 billion), which are not guaranteed.
• Vesting is contingent on continued service, meaning the options could be forfeited if the officer leaves the company before vesting.

Future Outlook

The performance-based vesting conditions for half of the granted options indicate a strategic focus on achieving significant market capitalization growth, ranging from $1.5 billion to $4.0 billion, suggesting management's long-term growth aspirations for Pulse Biosciences.

Industry Context

Stock option grants with performance-based vesting, particularly tied to market capitalization, are common executive compensation practices in the biotechnology and medical device sectors (where Pulse Biosciences likely operates) to align executive incentives with long-term shareholder value creation and growth.

Comparison to Industry Standards

• The grant of stock options to a Principal Accounting Officer is a standard executive compensation practice across industries, including biotech and medical technology.
• The inclusion of both time-based and performance-based vesting criteria is a robust approach to executive incentives, often seen in high-growth sectors where achieving specific market milestones is critical. For example, similar structures are observed in companies like Inari Medical (NARI) or Shockwave Medical (SWAV) which also operate in specialized medical device markets, where executive compensation is often tied to product milestones, revenue growth, or market cap targets.
• The specific market capitalization targets ($1.5 billion to $4.0 billion) are ambitious for a company of potentially smaller current size, reflecting significant growth expectations, comparable to the growth trajectories seen in successful emerging biotech firms.

Stakeholder Impact

• Shareholders: Potential positive impact through alignment of executive incentives with market capitalization growth, potentially leading to increased shareholder value if targets are met.
• Employees: May signal a commitment to retaining key talent and a focus on long-term company performance.

Next Steps

• Future SEC filings will report the vesting of these options as milestones are met or over time.
• Monitoring the company's progress towards the $1.5 billion to $4.0 billion market capitalization targets will be relevant for assessing the performance-based vesting.

Key Dates

Recommendation

Keywords

Pulse Biosciences, PLSE, Stock Option Grant, Executive Compensation, Form 4, SEC Filing, Steven Weber, Principal Accounting Officer, Equity Incentive, Performance Vesting, Market Capitalization